ISSN : 1301-5680
e-ISSN : 2149-8156
Turkish Journal of Thoracic and Cardiovascular Surgery     
The outcomes of transcatheter aortic valve implantation with Edwards SAPIEN or CoreValve devices: Single-center experience in Turkey
Mehmet Gül1, Aydın Yıldırım1, Nevzat Uslu1, Abdurrahman Eksik1, Mustafa Kemal Erol1, Hüseyin Uyarel2, Mehmet Ertürk1, Özgür Sürgit1, İhsan Bakır3
1Departments of Cardiology, İstanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey
2Department of Cardiology, Medical Faculty of Bezmialem Vakıf University, İstanbul, Turkey
3Departments of Cardiovascular Surgery, İstanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey
DOI : 10.5606/tgkdc.dergisi.2012.087
Background: This study aims to evaluate early- and midterm outcomes of transcatheter aortic valve implantation.

Methods: Between October 2010 and February 2012, 35 patients (16 males, 19 females; mean age 77.4±6.9 years; range 58 to 91 years) who were at high risk for surgery (EuroSCORE 26.0±9.9) and underwent transcatheter aortic valve implantation in our clinic were included. Edwards SAPIEN (n=27) and CoreValve prostheses (n=8) were implanted by transfemoral (n=33), transapical (n=1), and subclavian (n=1) approaches. The mean preoperative echocardiographic valve area was 0.6±0.1 cm2, while the mean transvalvular gradient was 53.3±8.0 mmHg.

Results: The procedural success rate was 97%. Following the procedure, the mean transvalvular gradient decreased to 9.8±2.7 mmHg, whereas the average aortic valve area increased to 1.9±0.2 cm2. The mean NYHA functional capacity reduced from 3.5±0.5 before the procedure to 1.4±0.6 at three months during follow-up (p<0.001). A significant increase in the mean left ventricular ejection fraction (LVEF) was observed at one month (52.5±10.4% versus 50.1±11.4%, p<0.001). Permanent pacemaker implantation was required in four patients (3 CoreValve, 1 Edwards SAPIEN). Four patients (%11.4) died within the first 30 days of follow-up. Nine patients died during a mean of nine months (range 0-17 months), including procedural mortality.

Conclusion: Our single-center procedural success rate and earlyand mid-term follow-up outcomes are promising for this patient group, showing consistency with the other studies in the world.

Keywords : Aortic valve stenosis; bioprosthetic valve; transcatheter aortic valve implantation
Viewed : 10122
Downloaded : 1963